PVPeter Vilmann

Peter Vilmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter Vilmann has a total of 274 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimizing EUS-guided tissue acquisition: An international, multi-institution expert consensus

    by Jintao Guo, Peter Vilmann, Alberto Larghi, Anand V. Sahai, Benedetto Mangiavillano, Carlos Robles-Medranda, Marc Giovannini, Takao Itoi, Juan J. Vila, Kensuke Kubota, et al.

    Background and Objectives: EUS-guided tissue acquisition (EUS-TA) techniques are evolving rapidly. Although several clinical guidelines exist, key procedural issues remain unresolved. This study aimed to identify these unmet needs and assess global practice patterns. Methods: A questionnaire was designed by the International Society for Endoscopic Ultrasound. We conducted a global, multi-institutional survey of corresponding authors who had published EUS-TA in the last 5 years. The survey was distributed and collected via email using the SurveyMonkey website. We analyzed the results by calculating agreement percentages for specific statements and by summarizing the most frequently selected options. Results: The survey was completed by 27 experts, all with extensive experience in EUS-TA (62.96% performing >200 cases annually). Consensus was achieved across 9 core domains. For subepithelial lesions, solid pancreatic masses, and most abdominal/extraluminal targets, histology was the preferred evaluation method, while cytology and histology were equally favored for biliary strictures and peritoneal carcinomatosis. For cytological assessment, 22G needles were recommended by 77.78% of experts; for histological assessment, 22G fine-needle biopsy (FNB) needles (specifically the Franseen design) were favored by 62.96%. For EUS-guided portal pressure gradient measurement, fine needles (22G/25G) were recommended by 85.18%, whereas for chronic liver fibrosis assessment, a 19G needle was preferred. For tumors requiring next-generation sequencing, the 22G FNB needle was the consensus choice, with most experts agreeing that establishing organoids requires at least one additional pass. The slow-pull technique was favored for most solid lesions (59.26%), and 85.19% agreed that FNB needles significantly reduced the need for rapid on-site evaluation, with macroscopic on-site evaluation preferred for assessing sample adequacy. For pancreatic cystic lesions, EUS-fine-needle aspiration was the most favored initial technique (51.85%), though routine DNA analysis was not recommended by most (63.0%). Antibiotic prophylaxis was supported by 48.15%, particularly when more invasive techniques were used. Most experts (96.03%) endorsed the fanning technique, and 59.26% did not believe needle-tract seeding risk was underestimated, though multiple passes were identified as the greatest contributing factor. Conclusions: Based on the responses, consensus recommendations were established for several fine-needle aspiration and fine-needle biopsy practice patterns. This international consensus guides controversial EUS-TA issues, which may help improve diagnostic efficacy and quality.

  • Open Access

    Preoperative EUS–guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study

    by Bojan Kovacevic, Claus Fristrup, Carsten P. Hansen, Michael B. Mortensen, Frank Mortensen, Jakob Kirkegård, Mogens T. Stender, Sönke Detlefsen, Peter Vilmann

    Background and Objectives: Pancreatic cancer is a highly aggressive malignancy with poor prognosis. Surgery is the only curative treatment, but it carries a significant risk of morbidity. The role of preoperative EUS-guided biopsy (EUS-B) in up-front resectable patients has been a matter of debate, with some centers strongly advocating its use, whereas others limit it to indeterminate cases. We aimed to examine whether preoperative EUS–guided biopsy (EUS-B) has an impact on overall survival (OS) using nationwide data. Methods: The data of patients who underwent curatively intended surgical resection for pancreatic cancer were retrieved from the prospectively maintained national Danish Pancreatic Cancer Group database. Associations between preoperative EUS-B and survival were evaluated using Kaplan-Meier plots and univariable and multivariable Cox proportional hazards models. OS was examined in the overall cohort and in a propensity score–matched subgroup, where EUS-B cases were matched to controls in a 1:2 ratio. Results: Between 2011 and 2023, 1889 patients who underwent surgery for pancreatic cancer constituted the overall cohort. The mean age was 67.4 (SD, 9.1) years, and 53.5% were male. The median overall survival was 28.5 months in the EUS-B group compared to 26.7 months in the non–EUS-B group (HR, 1.07; 95% CI, 0.91–1.26; P = 0.411). In the propensity score–matched subgroup ( n = 582), the median survival time was 28.6 months (EUS-B group) and 24.7 months (non–EUS-B group; HR, 1.04; 95% CI, 0.84–1.29; P = 0.691). Conclusions: Preoperative EUS-B did not influence survival in patients with pancreatic cancer in this nationwide retrospective study.


  • EUS-Guided Radiofrequency Ablation as a Minimally Invasive Treatment for Insulinomas—A Single-Center Experience

    by Bojan Kovacevic, Peter Vilmann, Lene Brink, Marianne Christina Klose, Mette Paulli Sonne, Ulrich Knigge, Mikkel Andreassen

    Context: Insulinomas, although rare, are among the most common functional pancreatic neuroendocrine neoplasms (pNENs), causing debilitating and recurrent hypoglycemic episodes and severely affecting quality of life. Objective: To evaluate endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) as a novel and minimally invasive treatment for insulinomas. Patients: We retrospectively identified patients at a single tertiary care center between 2022 and 2025 with a suspicion of insulinomas (based on a positive fasting test and imaging) who underwent EUS-RFA. Lesions considered for RFA were biopsy-proven pNENs with a Ki-67 index <10%, and <25 mm in size. All patients were hospitalized for 24 hours and EUS-RFA was conducted under general anesthesia using a dedicated EUS-RFA needle and under direct ultrasound guidance. Mean follow-up duration was 15.5 months. The primary outcome measure was clinical success (symptom improvement with a documented increase in blood glucose) and safety. Results: A total of 17 patients were identified and included. The mean age was 60.1 years and 53% were male. Normoglycemia was achieved after a single EUS-RFA session in 11 patients (64.7%), while 6 patients (35.3%) required a second EUS-RFA. The overall clinical success rate was 100% (n = 17/17; 95% CI: 80.4%-100.0%). A total of 4 adverse events were observed in 23 procedures (17.4%), 2 mild and 2 moderate (8.7%). Conclusion: EUS-RFA appears to provide complete symptom resolution and demonstrates a favorable safety profile compared to conventional surgery. However, the long-term efficacy of EUS-RFA remains to be determined.


  • Open Access

    Risk Factors for Common Bile Duct Stones in Patients with Previous Cholecystectomy: A Multicenter Prospective Proof-of-Concept Study

    by Andrea Lisotti, Thomas Togliani, Graziella Masciangelo, Angelo Bruni, Emilija Rakichevikj, Peter Vilmann, Vincenzo Giorgio Mirante, Pietro Fusaroli

    Objectives: Most studies assess risk factors for common bile duct (CBD) stones in patients with gallbladder in situ. We aimed to assess risk factors for CBD stones in patients with previous cholecystectomy in a proof-of-concept study. Methods: We enrolled consecutive patients undergoing EUS for suspected symptomatic CBD stones and recorded demographic variables, clinical presentation, liver function tests (LFTs), and transabdominal ultrasound (US) findings. EUS was used as gold standard for CBD stones. Multivariate analysis was used to identify risk factors in the training set; a model was created and tested on the validation set. Results: A total of 211 patients (25.6% male; median age, 66 [49–75] years old) were enrolled; 77.7% presented with abdominal pain, 30.3% with hyperbilirubinemia, 26.5% with pancreatitis, and 61.1% with LFT alterations. Ultrasound showed CBD dilation in 37.4% patients. Overall, 96 (45.5%) patients had CBD stones. According to multivariate analysis, male gender (OR 2.54 [1.26–5.09]; p = 0.009), age > 63 years (OR 3.06 [1.63–5.72]; p < 0.001), LFT alteration (OR 2.62 [1.40–4.91]; p = 0.003), and CBD dilation (OR 2.46 [1.31–4.65]; p = 0.005) were independently related to CBD stones. A model was created based on the number of risk factors on admission; patients with no risk factor had a 9.5% prevalence of CBD stones; those with one risk factor, 26.7%; two risk factors, 53.2%; three risk factors, 66.7%; and four risk factors, 100%. Conclusions: The results of this proof-of-concept study identify male gender, age, LFT alteration, and CBD dilation as risk factors for CBD stones in patients with previous cholecystectomy. An adequate assessment of the pre-test probability will guide patients’ subsequent management.


  • Open Access

    Validation of a Novel EUS-FNB-Derived Organoid Co-Culture System for Drug Screening in Patients with Pancreatic Cancer

    by Simon Ezban Grützmeier, Bojan Kovacevic, Peter Vilmann, Charlotte Vestrup Rift, Linea Cecilie Melchior, Morten Orebo Holmström, Lene Brink, Hazem Hassan, John Gásdal Karstensen, Hanne Grossjohann, et al.

    Cancer-associated fibroblasts (CAFs) have been shown to impact the chemosensitivity of patient-derived tumor organoids (PDTOs). However, the published literature comparing PDTO response to clinical outcome does not include CAFs in the models. Here, a co-culture model was created using PDTOs and CAFs derived from endoscopic ultrasound-guided fine-needle biopsies (EUS-FNBs) for potential use in drug screening applications. Co-cultures were established, and growth was compared to monocultures using image metrics and a commercially available assay. We were able to establish and expand validated malignant PDTOs from 19.2% of adenocarcinomas from EUS-FNBs. CAFs could be established from 25% of the samples. The viability of PDTOs in the mixed cell co-culture could be isolated using image metrics. The addition of CAFs promoted PDTO growth in half of the established co-cultures. These results show that co-cultures can be established from tiny amounts of tissue provided by EUS-FNB. An increased growth of PDTOs was shown in co-cultures, suggesting that the present setup successfully models CAF–PDTO interaction. Furthermore, we demonstrated that standard validation techniques may be insufficient to detect contamination with normal cells in PDTO cultures established from primary tumor core biopsies.


  • DRUG ADMINISTRATION INTO THE GASTROINTESTINAL WALL – EUS AS GUIDING TOOL

    by Henrik Pedersen, Kristina Rivera, Cody Cleveland, Anders Uhrenfeldt, Charlotte Dalsgaard, Monica Emerson, Antonino Azzarello, Mette Poulsen, Charlotte Gustafsson, Lise Gluud, et al.

  • Initial experiences with a novel EUS-FNB derived organoid coculture system for drug screening in patients with pancreatic cancer

    by S. Grützmeier, B. Kovacevic, J. G. Karstensen, L. Brink, H. Al-Hashemi, A. Toxværd, L. Melchior, E. Høgdall, J. P. Hasselby, P. Vilmann, et al.

    Aims Choice of chemotherapeutic treatment based on drug screening of patient-derived tumor organoids (PDTOs) may present a breakthrough in personalized medicine. Here we present our initial experiences with a next-generation organoid model, including PDTOs and patient-derived Cancer Associated-Fibroblasts (CAFs) from pancreatic cancer derived from EUS-FNB samples to use for drug screening purposes. Methods Patients were included prospectively with the purpose of creating cocultures for drug screening. PDTO and CAF cultures were established from EUS-FNB samples obtained during diagnostic procedures. Drug screening response was measured by analysis of image metrics. Results We included 39 patients (41 biopsy samples) undergoing a diagnostic EUS-FNB procedure. PDTOs could be established in 80%, but only expanded sufficiently for a potential drug screen in 37.5 % of cases if the corresponding biopsy was diagnostic for adenocarcinoma. Similar success rates were seen for CAFs. The addition of CAFs in cocultures significantly improved organoid viability during drug screening conditions (38% difference in organoid area, p = 0.045). Conclusions Advanced organoid cocultures could be created from EUS-FNB samples from pancreatic cancer and they may provide a more accurate disease model compared with traditional monocultures. However, challenges related to growing and expanding cells from biopsies may limit their clinical potential. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

    by Rikke Boedker Holmstroem, Ole Haagen Nielsen, Søren Jacobsen, Lene Buhl Riis, Susann Theile, Jacob Tveiten Bjerrum, Peter Vilmann, Julia Sidenius Johansen, Mogens Karsbøl Boisen, Rikke Helene Løvendahl Eefsen, et al.

    Background Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies of alternatives to glucocorticoids are lacking. We examined whether interleukin-6 blockade by tocilizumab reduced ICI-induced colitis and arthritis. Patients and methods Patients with solid cancer experiencing Common Terminology Criteria for Adverse Events (CTCAE v5.0) grade >1 ICI-induced colitis/diarrhea (n=9), arthritis (n=9), or both (n=2) were recruited and treated with tocilizumab (8 mg/kg) every 4 weeks until worsening or unacceptable toxicity. Patients were not allowed to receive systemic glucocorticoids and other immunosuppressive drugs within the 14-day screening period. The primary endpoint was clinical improvement of colitis and arthritis, defined as ≥1 grade CTCAE reduction within 8 weeks. Secondary endpoints were improvements and glucocorticoid-free remission at week 24; safety; radiologic, endoscopic, and histological changes; and changes in plasma concentrations of C reactive protein, cytokines (IL-6, IL-8, and IL-17), and YKL-40. Results Nineteen patients were available for efficacy analysis; one patient was excluded due to pancreatic insufficiency-induced diarrhea. Patients received treatment with pembrolizumab (n=10) or nivolumab (n=4) as monotherapy or ipilimumab and nivolumab (n=5) combined. Seven patients had been initially treated with glucocorticoids, and two of them also received infliximab. Ten patients continued ICI therapy during tocilizumab treatment. The primary endpoint was achieved in 15 of 19 (79%) patients. Additional one patient had ≥1 grade reduction at week 10, and another patient had stabilized symptoms. At week 24, ongoing improvement without glucocorticoids (n=12), including complete remission (n=10), was noted. Five patients had grades 3–4 treatment-related adverse events, which were manageable and reversible. Conclusions Tocilizumab showed promising clinical efficacy and a manageable safety profile in the treatment of ICI-induced colitis and arthritis. Our findings support the feasibility of randomized trials of immune-related adverse events. Trial registration number NCT03601611.


  • Combined ERCP and EUS Drainage for Hilar Stricture

    by John Gásdal Karstensen, Peter Vilmann